secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001613103-24-000162
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q2 revenue $8.4B (+5.3%); raises FY25 organic growth and EPS guidance
-------------------------------------------------------------------------------

- GAAP diluted EPS $0.99 (up 46% YoY); non-GAAP diluted EPS $1.26 (up 1% as reported, 8% constant currency).
- Revenue $8.403B, organic growth 5.0%; driven by TAVR, PFA, leadless pacemakers, Diabetes, Spine, Neuromodulation.
- FY25 organic revenue growth guidance raised to 4.75%-5% from 4.5%-5%; non-GAAP EPS guidance raised to $5.44-$5.50 from $5.42-$5.50.
- Diabetes revenue $686M (+12.4% as reported, +11% organic) on continued adoption of MiniMed 780G AID system.
- Cardiovascular portfolio revenue $3.102B (+6.1% as reported, +5.6% organic) with high-single digit growth in Structural Heart (Evolut FX+ TAVR launch).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000161310324000162/0001613103-24-000162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000161310324000162/mdt-20241119.htm
  HTML page:      https://secwatch.observer/filing/0001613103-24-000162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer